Budget Impact Analysis of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated with Docetaxel from the Perspective of the Brazilian Private Health Care System

Author(s):

V. Vitale ◽

E. Asano ◽

M.L. Pereira

Keyword(s):

Prostate Cancer ◽

Health Care ◽

Cancer Patients ◽

Impact Analysis ◽

Budget Impact ◽

Abiraterone Acetate ◽

Private Health Care ◽

Castration Resistant ◽

Previously Treated

Budget Impact Comparison of Abiraterone Acetate Plus Prednisone in the Pre-Chemotherapy Setting Followed by Enzalutamide in the Post-Chemotherapy Setting Versus the Opposite Treatment Sequence in Metastatic Castration-Resistant Prostate Cancer Patients Under the Brazilian Private Health Care System Perspective

Value in Health ◽

10.1016/j.jval.2016.03.1549 ◽

2016 ◽

Vol 19 (3) ◽

pp. A142

Author(s):

L Pititto ◽

E Asano

Keyword(s):

Prostate Cancer ◽

Health Care ◽

Cancer Patients ◽

Budget Impact ◽

Abiraterone Acetate ◽

Treatment Sequence ◽

Private Health Care ◽

System Perspective ◽

Cost Effectiveness of Abiraterone Acetate Plus Prednisone in the Pre-Chemotherapy Setting Followed by Enzalutamide in the Post-Chemotherapy Setting Versus the Opposite Treatment Sequence in Metastatic Castration-Resistant Prostate Cancer Patients Under the Brazilian Private Health Care System Perspective

Value in Health ◽

10.1016/j.jval.2016.03.1584 ◽

2016 ◽

Vol 19 (3) ◽

pp. A149 ◽

Author(s):

L Pititto ◽

E Asano

Keyword(s):

Prostate Cancer ◽

Health Care ◽

Cost Effectiveness ◽

Cancer Patients ◽

Abiraterone Acetate ◽

Treatment Sequence ◽

Private Health Care ◽

System Perspective ◽

Budget Impact Analysis of Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel in the Mexican Public Healthcare System

Value in Health ◽

10.1016/j.jval.2018.04.130 ◽

2018 ◽

Vol 21 ◽

pp. S21

Author(s):

JG Gay ◽

NM Schultz ◽

S Braun

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Healthcare System ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Public Healthcare ◽

Public Healthcare System ◽

713 ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL

The Journal of Urology ◽

10.1016/j.juro.2013.02.272 ◽

2013 ◽

Vol 189 (4S) ◽

Author(s):

Fred Saad ◽

Neal D Shore ◽

Hendrik Van Poppel ◽

Dana Rathkopf ◽

Matthew R. Smith ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Interim Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Prior Chemotherapy ◽

Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients

European Urology Oncology ◽

10.1016/j.euo.2019.01.008 ◽

2020 ◽

Vol 3 (1) ◽

pp. 119-127 ◽

Cited By ~ 2

Author(s):

Eleni Efstathiou ◽

Mark Titus ◽

Sijin Wen ◽

Patricia Troncoso ◽

Anh Hoang ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Abiraterone Acetate ◽

Activity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with ketoconazole (keto): A prospective phase II study from the Prostate Cancer Clinical Trials Consortium.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5039 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5039-5039 ◽

Author(s):

Won Kim ◽

John Wilton ◽

Li Zhang ◽

Amy M. Lin ◽

Lawrence Fong ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Phase Ii ◽

Phase Ii Study ◽

Abiraterone Acetate ◽

Cancer Clinical Trials ◽

Castration Resistant ◽

Prospective Phase ◽

Previously Treated

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel

Frontiers in Pharmacology ◽

10.3389/fphar.2017.00836 ◽

2017 ◽

Vol 8 ◽

Author(s):

Jian-Ri Li ◽

Kun-Yuan Chiu ◽

Shian-Shiang Wang ◽

Cheng-Kuang Yang ◽

Chuan-Shu Chen ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Abiraterone Acetate ◽

Combined Androgen Blockade ◽

Castration Resistant ◽

Androgen Blockade

Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-14-1549 ◽

2015 ◽

Vol 21 (14) ◽

pp. 3170-3177 ◽

Cited By ~ 36

Author(s):

Xu S. Xu ◽

Charles J. Ryan ◽

Kim Stuyckens ◽

Matthew R. Smith ◽

Fred Saad ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Prostate Specific Antigen ◽

Specific Antigen ◽

Abiraterone Acetate ◽

MP73-13 BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FROM A US PAYER PERSPECTIVE

The Journal of Urology ◽

10.1016/j.juro.2015.02.2689 ◽

2015 ◽

Vol 193 (4S) ◽

Author(s):

Ken O'Day ◽

Cat N. Bui ◽

Scott Flanders ◽

Nina Oestreicher ◽

Peter Francis ◽

...

Keyword(s):

Prostate Cancer ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Castration Resistant ◽

Payer Perspective

772 Which factors predict overall survival in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate post-docetaxel?

European Urology Supplements ◽

10.1016/s1569-9056(16)60774-1 ◽

2016 ◽

Vol 15 (3) ◽

pp. e772-e772a

Author(s):

C. Van Praet ◽

S. Rottey ◽

F. Van Hende ◽

G. Pelgrims ◽

W. Demey ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Abiraterone Acetate ◽